NASDAQ:AMRS - Amyris Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$4.09 -0.12 (-2.85 %)
(As of 12/16/2018 04:00 PM ET)
Previous Close$4.09
Today's Range$3.98 - $4.23
52-Week Range$3.19 - $9.28
Volume1.08 million shs
Average Volume1.50 million shs
Market Capitalization$294.12 million
P/E Ratio-1.34
Dividend YieldN/A
Beta0.16
Amyris, Inc., an integrated renewable products company, engages in the research, development, and production of ingredients for the health and wellness, clean beauty, and flavors and fragrances markets worldwide. It applies its bioscience solutions to convert plant sugars into hydrocarbon molecules and produce specialty ingredients and consumer products. The company delivers its products and services under the No Compromise name across various markets, including specialty and performance chemicals, flavors and fragrances, cosmetics ingredients, pharmaceuticals, and nutraceuticals. It has a collaboration agreement with Yifan Pharmaceutical Co., Ltd. and Givaudan SA. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.

Receive AMRS News and Ratings via Email

Sign-up to receive the latest news and ratings for AMRS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Industrial organic chemicals
Sub-IndustryOil & Gas Refining & Marketing
SectorBasic Materials
Current SymbolNASDAQ:AMRS
Previous Symbol
CUSIP03236M10
Phone510-450-0761

Debt

Debt-to-Equity RatioN/A
Current Ratio0.44
Quick Ratio0.40

Price-To-Earnings

Trailing P/E Ratio-1.34
Forward P/E Ratio-3.05
P/E GrowthN/A

Sales & Book Value

Annual Sales$143.45 million
Price / Sales2.05
Cash FlowN/A
Price / Cash FlowN/A
Book Value($4.64) per share
Price / Book-0.88

Profitability

EPS (Most Recent Fiscal Year)($3.05)
Net Income$-72,320,000.00
Net Margins-114.09%
Return on EquityN/A
Return on Assets-127.95%

Miscellaneous

Employees414
Outstanding Shares71,910,000
Market Cap$294.12 million
OptionableOptionable

Amyris (NASDAQ:AMRS) Frequently Asked Questions

What is Amyris' stock symbol?

Amyris trades on the NASDAQ under the ticker symbol "AMRS."

When did Amyris' stock split? How did Amyris' stock split work?

Amyris's stock reverse split on Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2017. An investor that had 100 shares of Amyris stock prior to the reverse split would have 7 shares after the split.

How were Amyris' earnings last quarter?

Amyris Inc (NASDAQ:AMRS) announced its quarterly earnings results on Tuesday, November, 13th. The biotechnology company reported ($1.13) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.96. The biotechnology company earned $14.90 million during the quarter, compared to the consensus estimate of $46.72 million. The company's revenue was down 38.4% on a year-over-year basis. During the same period in the prior year, the business earned ($0.81) earnings per share. View Amyris' Earnings History.

When is Amyris' next earnings date?

Amyris is scheduled to release their next quarterly earnings announcement on Thursday, March 21st 2019. View Earnings Estimates for Amyris.

What price target have analysts set for AMRS?

2 analysts have issued twelve-month price objectives for Amyris' shares. Their forecasts range from $8.00 to $11.00. On average, they expect Amyris' stock price to reach $9.50 in the next twelve months. This suggests a possible upside of 132.3% from the stock's current price. View Analyst Price Targets for Amyris.

What is the consensus analysts' recommendation for Amyris?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Amyris.

What are Wall Street analysts saying about Amyris stock?

Here are some recent quotes from research analysts about Amyris stock:
  • 1. According to Zacks Investment Research, "Amyris INC is an integrated renewable products company applying industrial synthetic biology to genetically modify microorganisms to serve as living factories. Amyris designs these microorganisms to produce defined molecules for use as renewable chemicals and transportation fuels. The Company is engaged in the development of farmesene- a molecule, which serves as the base chemical building block for a wide range of renewable products to replace existing products that are derived from petroleum, plant or animal sources and that may be of lower quality or higher price. Amyris INC is headquartered in Emeryville, CA. " (11/19/2018)
  • 2. HC Wainwright analysts commented, "We expect the company’s topline to grow at a five-year CAGR of 30.7% from $185.9M in 2018 to $715.6M in 2023. We expect mid- to long-term gross margins to fluctuate between 60-70%, driven by lumpiness of the high margin revenues from grants and collaboration. We are projecting operating expenses to grow at a five-year CAGR of 7.4% from 2018 to 2023. We expect the company to achieve EBITDA profitability during 2018. Based on these assumptions, we arrive at a valuation of $15.00 per share for AMRS stock." (9/28/2018)

Has Amyris been receiving favorable news coverage?

Media coverage about AMRS stock has been trending somewhat positive on Sunday, InfoTrie reports. InfoTrie identifies positive and negative press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Amyris earned a news impact score of 1.0 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 4.0 out of 10, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the near term.

Who are some of Amyris' key competitors?

Who are Amyris' key executives?

Amyris' management team includes the folowing people:
  • Mr. John G. Melo, Pres, CEO & Director (Age 52)
  • Ms. Kathleen Valiasek, Chief Financial Officer (Age 54)
  • Mr. Eduardo Alvarez, Chief Operating Officer (Age 54)
  • Ms. Nicole Kelsey, Gen. Counsel & Sec. (Age 51)
  • Dr. Joel R. Cherry, Pres of R&D (Age 57)

Who are Amyris' major shareholders?

Amyris' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Vivo Capital LLC (8.00%), BlackRock Inc. (3.56%), Vanguard Group Inc. (1.66%), Vanguard Group Inc (1.66%), Gilder Gagnon Howe & Co. LLC (1.54%) and AWM Investment Company Inc. (1.16%). Company insiders that own Amyris stock include (Mauritius) Pte Ltd Maxwell, Eduardo Alvarez, Frank Kung, John Melo, Kathleen Valiasek, L John Doerr and Patrick Y Yang. View Institutional Ownership Trends for Amyris.

Which institutional investors are selling Amyris stock?

AMRS stock was sold by a variety of institutional investors in the last quarter, including Compagnie Lombard Odier SCmA, Engineers Gate Manager LP, Vanguard Group Inc. and Vanguard Group Inc. Company insiders that have sold Amyris company stock in the last year include (Mauritius) Pte Ltd Maxwell, Frank Kung, John Melo and L John Doerr. View Insider Buying and Selling for Amyris.

Which institutional investors are buying Amyris stock?

AMRS stock was bought by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Gilder Gagnon Howe & Co. LLC, AWM Investment Company Inc., BlackRock Inc., Northpointe Capital LLC, B. Riley Financial Inc., Allianz Asset Management GmbH and JPMorgan Chase & Co.. Company insiders that have bought Amyris stock in the last two years include Eduardo Alvarez, Kathleen Valiasek and Patrick Y Yang. View Insider Buying and Selling for Amyris.

How do I buy shares of Amyris?

Shares of AMRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amyris' stock price today?

One share of AMRS stock can currently be purchased for approximately $4.09.

How big of a company is Amyris?

Amyris has a market capitalization of $294.12 million and generates $143.45 million in revenue each year. The biotechnology company earns $-72,320,000.00 in net income (profit) each year or ($3.05) on an earnings per share basis. Amyris employs 414 workers across the globe.

What is Amyris' official website?

The official website for Amyris is http://www.amyris.com.

How can I contact Amyris?

Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-450-0761 or via email at [email protected]


MarketBeat Community Rating for Amyris (NASDAQ AMRS)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  232 (Vote Outperform)
Underperform Votes:  303 (Vote Underperform)
Total Votes:  535
MarketBeat's community ratings are surveys of what our community members think about Amyris and other stocks. Vote "Outperform" if you believe AMRS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMRS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 12/16/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel